Bremelanotide (PT-141) Information & Coordination for Licensed U.S. Clinics
Bremelanotide is a melanocortin receptor agonist. The FDA-approved prescription product Vyleesi contains bremelanotide and is approved for a specific indication in certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Vyleesi is approved under NDA 210557.
The shorthand term “PT-141” is also used in connection with bremelanotide-related products. It should not, however, be treated as interchangeable with the FDA-approved Vyleesi product. A different preparation marketed or described as PT-141 does not automatically share Vyleesi’s formulation, labeling, or FDA approval.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, compounder, wholesaler, distributor, or dispensing entity.
What Clinics Should Know About Bremelanotide
Current Vyleesi prescribing information identifies bremelanotide as a melanocortin receptor agonist indicated for premenopausal women with acquired, generalized HSDD when the condition is not attributable to a co-existing medical or psychiatric condition, relationship problems, or the effects of another medication or drug substance.
The labeling also states that Vyleesi is:
- not indicated for HSDD in postmenopausal women;
- not indicated for HSDD in men; and
- not indicated to enhance sexual performance.
Phoenix therefore does not present PT-141 as a general treatment for erectile dysfunction, male sexual dysfunction, performance enhancement, or broad sexual-wellness purposes.
Diagnosis, patient selection, prescribing, monitoring, and treatment decisions remain with appropriately licensed healthcare professionals.
PT-141 and Vyleesi Are Not Interchangeable Terms
Product identity matters.
The FDA-approved Vyleesi product has a defined formulation, labeling, route of administration, and approval under NDA 210557. Current DailyMed information identifies bremelanotide acetate as the ingredient supplying the active bremelanotide moiety.
The shorthand name “PT-141” does not establish that a particular preparation is Vyleesi or that it has been reviewed or approved by FDA.
This distinction is especially important when evaluating compounded or independently marketed products.
In August 2026, FDA issued warning letters involving products marketed as “PT-141 (Bremelanotide)” where the agency determined that those specific products had no approved applications in effect and were being marketed as unapproved new drugs. Those enforcement actions involved the particular products and companies identified by FDA; they should not be used to characterize the approved Vyleesi product itself.
How Bremelanotide Works
Bremelanotide interacts with several melanocortin receptor subtypes.
FDA labeling states that bremelanotide nonselectively activates multiple melanocortin receptors, with MC1R and MC4R being particularly relevant at therapeutic exposure. Importantly, FDA also states that the mechanism by which Vyleesi improves HSDD is unknown.
For that reason, Phoenix does not describe PT-141 as simply “switching on” sexual desire, directly increasing arousal, or working through one established neurological pathway.
Those descriptions go beyond what the current approved labeling supports.
Current FDA and Compounding Status
FDA approval of Vyleesi does not automatically extend to compounded products marketed as PT-141. Sections 503A and 503B have separate requirements, and eligibility depends on the specific substance, preparation, and compounding entity.
FDA has previously raised 503A concerns involving compounded bremelanotide, and bremelanotide is not currently included on FDA’s 503B Bulks List.
Phoenix therefore does not represent PT-141 as having an automatic 503A or 503B pathway. Any proposed pathway requires review by the responsible licensed pharmaceutical and regulatory parties.
Why Product Documentation Matters
A reference to “PT-141” by itself does not establish:
- the precise drug substance;
- whether the preparation is Vyleesi or another product;
- FDA approval status;
- the applicable compounding pathway;
- manufacturer or compounder identity;
- product quality; or
- regulatory eligibility.
Those questions require review of the actual product and supporting documentation.
Phoenix may help licensed healthcare organizations organize available documentation and publicly available regulatory information, but we do not independently determine that a pharmaceutical preparation is approved, legally compoundable, clinically appropriate, or suitable for dispensing.
How Phoenix Meds Supports Licensed Clinics
Our role is administrative.
We may assist licensed healthcare organizations with professional credential review, organization of available documentation, review of publicly available FDA and licensing information, and administrative communication concerning documentation.
Our support may include:
- professional and facility credential review;
- organization of available product documentation;
- review of publicly available labeling and regulatory information;
- identification of inconsistencies in product descriptions or documentation; and
- administrative follow-up concerning information that requires review by the appropriate licensed or regulatory party.
Phoenix’s administrative review is not FDA approval, pharmacy accreditation, clinical advice, or a legal opinion.
Safety and Labeling Considerations
The FDA-approved Vyleesi prescribing information contains clinically important contraindications, warnings, precautions, adverse reactions, and drug-interaction information.
For example, current labeling includes cardiovascular considerations and other safety information that licensed clinicians should evaluate in the context of the individual patient.
Phoenix does not interpret these warnings for individual patients, determine treatment eligibility, or provide patient-specific clinical recommendations.
We also do not certify the purity, potency, sterility, authenticity, safety, effectiveness, or clinical suitability of compounded or independently marketed bremelanotide preparations.
Bremelanotide Administrative Coordination for Licensed Clinics
Licensed healthcare organizations may contact Phoenix Meds Inc. for administrative support relating to professional credentials, documentation, product information, and publicly available regulatory materials concerning bremelanotide. An administrative inquiry is not a medication order and does not establish FDA approval, product availability, compounding eligibility, clinical appropriateness, or permission to distribute or dispense a particular preparation.
Clinic Verification
Professional and facility credentials may be reviewed as part of Phoenix Meds administrative process.
Documentation Review
Licensed Parties
Frequently Asked Questions
Is PT-141 FDA approved?
The more precise statement is that Vyleesi, a specific bremelanotide prescription drug product, is FDA approved under NDA 210557.
A different preparation marketed as “PT-141,” including a compounded or independently marketed preparation, should not be represented as FDA approved merely because it contains bremelanotide or uses the PT-141 name.
What is Vyleesi FDA approved to treat?
Current labeling limits Vyleesi’s indication to certain premenopausal women with acquired, generalized HSDD meeting the criteria described in the prescribing information. It is not indicated for men, postmenopausal women, or enhancement of sexual performance.
Is PT-141 FDA approved for erectile dysfunction in men?
Vyleesi’s current FDA-approved labeling does not include treatment of erectile dysfunction in men. Its labeling specifically states that Vyleesi is not indicated for treatment of HSDD in men.
Does bremelanotide work only through the MC4 receptor?
No. FDA labeling describes bremelanotide as acting on several melanocortin receptor subtypes. It also states that the mechanism through which Vyleesi improves HSDD is unknown.
Does Vyleesi's FDA approval mean compounded PT-141 is also FDA approved?
No. FDA approval applies to the approved Vyleesi product under its NDA. A compounded drug is a separate preparation and does not automatically acquire the approved product’s FDA status.
Is PT-141 automatically eligible for 503A or 503B compounding?
No automatic pathway should be assumed. Sections 503A and 503B contain separate statutory requirements, and the exact bulk substance, preparation, compounding entity, and circumstances require product-specific review. FDA has previously taken enforcement action involving compounded Bremelanotide (PT-141) that did not meet applicable 503A conditions in the circumstances reviewed.
Does Phoenix Meds compound or dispense bremelanotide?
oes Phoenix Meds provide dosing or treatment protocols?
No. Phoenix Meds does not provide patient-specific dosing, administration instructions, treatment protocols, or clinical recommendations.
What can Phoenix Meds help licensed clinics with?
Our role is administrative and may include credential review, organization of documentation, review of publicly available regulatory information, and professional communication concerning that documentation.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, compounder, wholesaler, distributor, prescriber, or dispensing entity.
This page does not represent a compounded or independently marketed PT-141 preparation as FDA approved and does not establish that any particular strength, formulation, compounding pathway, distribution pathway, or clinical use is available or permitted.
Regulatory References
- Vyleesi (Bremelanotide Injection) — Current U.S. Prescribing Information
- Vyleesi (Bremelanotide) — FDA NDA 210557 Multidiscipline Review
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- Tailor Made Compounding LLC — FDA Warning Letter, April 1, 2020
- Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act
- 503B Bulk Drug Substances List
- Peptide Partners LLC — FDA Warning Letter, August 24, 2026